Enteric Infections, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Microb Genom. 2018 Apr;4(4). doi: 10.1099/mgen.0.000171. Epub 2018 Mar 29.
Shigella are ranked among the most prevalent aetiologies of diarrhoeal disease worldwide, disproportionately affecting young children in developing countries and high-risk communities in developed settings. Antimicrobial treatment, most commonly with fluoroquinolones, is currently recommended for Shigella infections to alleviate symptoms and control disease transmission. Resistance to fluoroquinolones has emerged in differing Shigella species (S. dysenteriae, flexneri and sonnei) since the turn of the 21st century, originating in endemic areas, and latterly spreading into non-endemic regions. Despite occurring independently, the emergence of fluoroquinolone resistance in these different Shigella species shares striking similarities regarding their epidemiology and resistance mechanisms. Here, we review and discuss the current epidemiology of fluoroquinolone-resistant Shigella species, particularly in the light of recent genomic insights.
志贺氏菌属是全球最常见的腹泻病病因之一,在发展中国家的幼儿和发达国家的高风险人群中发病率不成比例。目前建议使用抗菌药物(最常见的是氟喹诺酮类药物)治疗志贺氏菌感染,以缓解症状和控制疾病传播。自 21 世纪初以来,不同的志贺氏菌(痢疾志贺氏菌、福氏志贺氏菌和宋内志贺氏菌)出现了对氟喹诺酮类药物的耐药性,这种耐药性最初出现在流行地区,后来传播到非流行地区。尽管是独立出现的,但这些不同志贺氏菌种中氟喹诺酮类药物耐药性的出现,在流行病学和耐药机制方面具有惊人的相似之处。在这里,我们回顾和讨论了氟喹诺酮类耐药志贺氏菌种的当前流行病学情况,特别是根据最近的基因组研究结果。